Cargando…

Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis

BACKGROUND: Paediatric-onset multiple sclerosis (POMS) therapeutic approach derives from of adult-onset multiple sclerosis (AOMS) tailored algorithms. OBJECTIVES: To evaluate in a common clinical scenario the efficacy and safety of alemtuzumab (ALZ) in POMS and AOMS. METHODS: All patients switching...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puthenparampil, Marco, Gaggiola, Marta, Miscioscia, Alessandro, Mauceri, Valentina Annamaria, De Napoli, Federica, Zanotelli, Giovanni, Anglani, Mariagiulia, Nosadini, Margherita, Sartori, Stefano, Perini, Paola, Rinaldi, Francesca, Gallo, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10559704/ https://www.ncbi.nlm.nih.gov/pubmed/37808246 http://dx.doi.org/10.1177/17562864231177196

Ejemplares similares

Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis
por: Margoni, Monica, et al.
Publicado: (2019)

Case Report: Para-infectious cranial nerve palsy after bacterial meningitis
por: Zanotelli, Giovanni, et al.
Publicado: (2022)

NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis
por: Puthenparampil, Marco, et al.
Publicado: (2018)

Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy
por: Rinaldi, Francesca, et al.
Publicado: (2017)

Natalizumab safety in paediatric-onset multiple sclerosis at the time of SARS-Cov-2 pandemic
por: Margoni, Monica, et al.
Publicado: (2020)

Decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinically silent phenomenon
por: Puthenparampil, Marco, et al.
Publicado: (2017)

Alemtuzumab/natalizumab/ocrelizumab: COVID-19: 3 case reports
Publicado: (2021)

Efficacy of alemtuzumab and natalizumab in the treatment of different stages of multiple sclerosis patients
por: Wang, Li, et al.
Publicado: (2018)

Alemtuzumab/cladribine/natalizumab: Lymphopenia and COVID-19 infection: case report
Publicado: (2021)

Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis
por: Miscioscia, Alessandro, et al.
Publicado: (2022)

Neurodegeneration in the retina of motoneuron diseases: a longitudinal study in amyotrophic lateral sclerosis and Kennedy’s disease
por: Miscioscia, Alessandro, et al.
Publicado: (2023)

High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study
por: Malucchi, Simona, et al.
Publicado: (2016)

Early red nucleus atrophy in relapse‐onset multiple sclerosis
por: Margoni, Monica, et al.
Publicado: (2020)

BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset
por: Puthenparampil, M., et al.
Publicado: (2017)

The sequential natalizumab – alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial – Part I: Rationale and objectives
por: Hussain, Rehana Z, et al.
Publicado: (2022)

Short lasting activity-related headaches with sudden onset in children: a case-based reasoning on classification and diagnosis
por: Toldo, Irene, et al.
Publicado: (2013)

Hyper-Reflecting Foci in Multiple Sclerosis Retina Associate With Macrophage/Microglia-Derived Cytokines in Cerebrospinal Fluid
por: Puthenparampil, Marco, et al.
Publicado: (2022)

Therapy of Pediatric-Onset Multiple Sclerosis: State of the Art, Challenges, and Opportunities
por: Margoni, Monica, et al.
Publicado: (2021)

Alemtuzumab-related thyroid disease in people with multiple sclerosis is associated with age and brainstem phenotype at disease onset
por: Yap, Siew Mei, et al.
Publicado: (2020)

Acute Hepatitis with Positive Autoantibodies: A Case of Natalizumab-Induced Early-Onset Liver Injury
por: Cunha-Silva, Marlone, et al.
Publicado: (2022)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

Progress in the Management of Paediatric-Onset Multiple Sclerosis
por: Luchesa Smith, Aphra, et al.
Publicado: (2020)

A Model-Based Economic Evaluation of Cladribine Versus Alemtuzumab, Ocrelizumab and Natalizumab for the Treatment of Relapsing-Remitting Multiple Sclerosis with High Disease Activity in Chile
por: Espinoza, Manuel Antonio, et al.
Publicado: (2021)

Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence
por: Signoriello, Elisabetta, et al.
Publicado: (2023)

D-KEFS ST Failure Identifies Multiple Sclerosis Patients With Worse Objective and Self-Perceived Physical and Cognitive Disability
por: Riccardi, Alice, et al.
Publicado: (2019)

Familial localized scleroderma with paediatric onset: a review
por: Yurtsever, Ida, et al.
Publicado: (2021)

Genetic sharing and heritability of paediatric age of onset autoimmune diseases
por: Li, Yun R., et al.
Publicado: (2015)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Alemtuzumab in Covid era
por: Iovino, Aniello, et al.
Publicado: (2021)

Evidence of Streptococcal Infection in a new onset Paediatric OCD
Publicado: (2022)

The Clinical and Epidemiological Profile of Paediatric-Onset Multiple Sclerosis in Poland
por: Brola, Waldemar, et al.
Publicado: (2022)

Sudden onset headaches in paediatric emergency departments: diagnosis and management
por: Lenglart, Léa, et al.
Publicado: (2023)

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS
por: Ghezzi, Angelo, et al.
Publicado: (2019)

Performance on verbal fluency in late-onset schizophrenia is more preserved than in early-onset schizophrenia
por: Abdullina, E., et al.
Publicado: (2021)

Alemtuzumab in the up-front setting
por: Kaufman, Matthew, et al.
Publicado: (2008)

Alemtuzumab in chronic lymphocytic leukemia
por: Fraser, G., et al.
Publicado: (2007)

Alemtuzumab in the treatment of multiple sclerosis
por: Fernandez, Óscar
Publicado: (2014)

Alemtuzumab for the treatment of multiple sclerosis
por: Willis, Mark D, et al.
Publicado: (2015)

Alemtuzumab in refractory Sézary syndrome
por: Reifs, Carmen María Alcántara, et al.
Publicado: (2016)

Transition and transfer of the patient with paediatric-onset lupus: a practical approach for paediatric and adult rheumatology practices
por: Sadun, Rebecca E, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vsmsi23aepu17tem456s6ivmd4